Bioline Rx Stock Cash Flow From Operations

BLRX Stock  ILS 8.10  0.10  1.25%   
BioLine RX fundamentals help investors to digest information that contributes to BioLine RX's financial success or failures. It also enables traders to predict the movement of BioLine Stock. The fundamental analysis module provides a way to measure BioLine RX's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLine RX stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioLine RX Company Cash Flow From Operations Analysis

BioLine RX's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Operating Cash Flow

 = 

EBITDA

-

Taxes

More About Cash Flow From Operations | All Equity Analysis

Current BioLine RX Cash Flow From Operations

    
  (23.57 M)  
Most of BioLine RX's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLine RX is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Competition

In accordance with the recently published financial statements, BioLine RX has (23.57 Million) in Cash Flow From Operations. This is 104.47% lower than that of the Biotechnology sector and 137.7% lower than that of the Health Care industry. The cash flow from operations for all Israel stocks is 102.43% higher than that of the company.

BioLine Cash Flow From Operations Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLine RX's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioLine RX could also be used in its relative valuation, which is a method of valuing BioLine RX by comparing valuation metrics of similar companies.
BioLine RX is currently under evaluation in cash flow from operations category among its peers.

BioLine Fundamentals

About BioLine RX Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioLine RX's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLine RX using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLine RX based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in BioLine Stock

BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.